Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Association of Risk Reducing Surgery in BRCA 1 or BRCA 2 Mutation Carriers with Cancer Risk and Mortality
Domchek, et. al. JAMA. 2010;304(9):967-975.
Conclusions: Among a cohort of women with BRCA1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower risk of breast cancer; risk-reducing salpingo-oophorectomy was associated with a lower risk of ovarian cancer, first diagnosis of breast cancer, all-cause mortality, breast cancer–specific mortality, and ovarian cancer–specific mortality.
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
Timothy R. Rebbeck, Noah D. Kauff and Susan M. Domchek. JNCI J Natl Cancer Inst (2009) 101 (2): 80-87.
Conclusion: The summary estimates presented here indicate that RRSO is strongly associated with reductions in the risk of breast, ovarian, and fallopian tube cancers and should provide guidance to women in planning cancer risk reduction strategies.
Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study
Noah D. Kauff, et. al. JCO March 10, 2008 vol. 26 no. 8 1331-1337.
Conclusion: The protection conferred by RRSO against breast and gynecologic cancers may differ between carriers of BRCA1 and BRCA2 mutations. Further studies evaluating the efficacy of risk-reduction strategies in BRCA mutation carriers should stratify by the specific gene mutated.
Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group
Timothy R. Rebbeck, et. al. JCO November 1, 2005 vol. 23 no. 31 7804-7810.
Conclusion: Short-term HRT use does not negate the protective effect of BPO on subsequent breast cancer risk in BRCA1/2 mutation carriers.
Primary Fallopian Tube Malignancies in BRCA-Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction
Michael J. Callahan, Christopher P. Crum, et. al. JCO September 1, 2007 vol. 25 no. 25 3985-3990.
Conclusion: The distal fallopian tube seems to be the dominant site of origin for early malignancies detected in approximately 6% of women undergoing ovarian cancer risk-reduction surgery.
The effect of total hysterectomy on specific sexual sensations
Martha F. Goetsch. American Journal of Obstetrics and Gynecology, Volume 196, Issue 6: p. 1922-1927, June 2005.
Conclusion: An indicated total hysterectomy will likely increase sexual satisfaction and not change the effect of breast stimulation. The few women with disturbingly reduced sexual sensation deserve assessment and treatment.
Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation Carriers: Role of Serial Sectioning in the Detection of Occult Malignancy
C. Bethan Powell, Eric Kenley, Lee-may Chen, Beth Crawford, Jane McLennan, Charles Zaloudek, Miriam Komaromy, Mary Beattie, John Ziegler. Journal of Clinical Oncology, Volume 23, Number 1:p. 127-132, January 2005.
Conclusion: A rigorous operative and pathologic protocol for RRSO increases the detection rate of occult ovarian malignancy in BRCA mutation carriers nearly seven-fold. If confirmed, this finding will alter postoperative management because additional staging, chemotherapy, and follow-up may be necessary in affected women.
BRCA germline mutations in Jewish women with uterine serous papillary carcinoma
Ofer Lavie, Gila Hornreich, Alon Ben-Arie, Gad Rennert, Yoram Cohen, Rehuven Keidar, Shlomi Sagi, Efrat Levy Lahad, Ron Auslander and Uzi Beller. Gynecologic Oncology, Volume 92, Number 2: p. 521-524, February 2004.
Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing
Jeffrey R. Botkin, Ken R. Smith, Robert T. Croyle, Bonnie J. Baty, Jean E. Wylie, Debra Dutson, Anna Chan, Heidi A. Hamann, Caryn Lerman, Jamie McDonald, Vickie Venne, John H. Ward, Elaine Lyon. American Journal of Medical Genetics. Volume 118A, Issue 3: p. 201-209, February 2003.
Effect of Prevention Strategies on Survival and Quality-Adjusted Survival of Women With BRCA1/2 Mutations: An Updated Decision Analysis
Victor R. Grann, Judith S. Jacobson, Dustin Thomason, Dawn Hershman, Daniel F. Heitjan, Alfred I. Neugut. Journal of Clinical Oncology. Volume 20, Issue 10: p. 2520-2529, May 2002.
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Timothy R. Rebbeck, Ph.D., Henry T. Lynch, M.D., Susan L. Neuhausen, Ph.D., Steven A. Narod, M.D., Laura van't Veer, Ph.D., Judy E. Garber, M.D., M.P.H., Gareth Evans, M.D., Claudine Isaacs, M.D., Mary B. Daly, M.D., Ph.D., Ellen Matloff, M.S., Olufunmilayo I. Olopade, M.D., Barbara L. Weber, M.D. New England Journal of Medicine. Volume 346: p. 1616-1622, May 2002. (Note: a review of the above two articles on oophorectomy and breast and ovarian cancer risk appears in the same issue of the New England Journal of Medicine.)
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
Lauren Scheuer, Noah Kauff, Mark Robson, Bridget Kelly, Richard Barakat, Jaya Satagopan, Nathan Ellis, Martee Hensley, Jeff Boyd, Patrick Borgen, Larry Norton, Kenneth Offit. Journal of Clinical Oncology. Volume 20, Issue 5: p. 1260-1268, March 2002.
Natural Hormone Replacement Therapy: What It Is and What Consumers Really Want
Dana Reed-Kane, PharmD, FIACP, FACA. International Journal of Pharmaceutical Compounding. Volume 5, Number 5: p. 332-335. September/October 2001
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
Steven A Narod, Ping Sun, Parviz Ghadirian, Henry Lynch, Claudine Isaacs, Judy Garber, Barbara Weber, Beth Karlan, David Fishman, Barry Rosen, Nadine Tung, Susan L Neuhausen. Lancet. Volume 12, Issue 357(9267): p. 1467-70, May 2001.